5-HT1A receptor, an old target for new therapeutic agents.
The serotonin receptor subtype 5 HT(1A) was one of the first serotonin receptor subtypes pharmacologically characterized. Over the last twenty years the 5 HT(1A) receptor has been the object of intense research efforts as witnessed by the 5 HT(1A) acting drugs marketed as anxiolytics. In recent years, several new chemical entities targeting the 5 HT(1A) receptor (alone or in combination with other molecular targets) have been proposed for novel therapeutic indications (neuroprotection, cognitive impairment, Parkinson Disease and related disorders, pain treatment). The present review will focus on those 5 HT(1A) receptor agents that entered preclinical trials starting from 2000.
Lacivita
Enza
E
Università degli Studi di Bari, Dipartimento Farmaco-Chimico, via Orabona, 4, 70125, Bari, Italy. leopoldo@farmchim.uniba.it.
Leopoldo
Marcello
M
Berardi
Francesco
F
Perrone
Roberto
R
D000700:Analgesics / Q000737:chemistry / Q000494:pharmacology*; D014151:Anti-Anxiety Agents / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D015394:Molecular Structure; D018696:Neuroprotective Agents / Q000737:chemistry / Q000494:pharmacology*; D044282:Receptor, Serotonin, 5-HT1A / Q000378:metabolism*; D013329:Structure-Activity Relationship
D000700:Analgesics; D014151:Anti-Anxiety Agents; D018696:Neuroprotective Agents; D044282:Receptor, Serotonin, 5-HT1A